{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:46:49Z","timestamp":1761893209974,"version":"3.37.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T00:00:00Z","timestamp":1545782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Elevations of fasting glucose (FG) levels are frequently encountered in people treated with thiazide diuretics. The risk is lower in people treated with ACE inhibitors (ACEi). To determine if genetic factors play a role in FG elevation, we examined the interaction of a diabetes gene risk score (GRS) with the use of 3 different antihypertensive medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We examined 376 nondiabetic hypertensive individuals with baseline FG &amp;lt;100 mg\/dl who were genotyped for 24 genes associated with risk of elevated glucose levels. All participants had \u22651 follow-up FG level over 6 years of follow-up. Participants were randomized to treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACEi (lisinopril). Outcomes were an FG increase of \u226513 or \u226527 mg\/dl, the upper 75% and 90% FG increase in the parent cohort from which the present cohort was obtained. Odds ratios were adjusted for factors that increase FG levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>For every 1 allele increase in GRS, the adjusted odds ratios (ORs) were 1.06 (95% confidence interval (CI): 0.99, 1.14; P = 0.06) and 1.09 (95% CI: 0.99, 1.20; P = 0.08). When results were examined by randomized medications, participants randomized to amlodipine had statistically significant odds for either outcome (OR: 1.23; 95% CI: 1.03, 1.48; P = 0.01 and OR: 1.31; 95% CI: 1.06, 1.62; P = 0.01). No such risk increase was found in participants randomized to the other 2 medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>A diabetes GRS predicts FG elevation in people treated with a CCB, but not with an ACEi or diuretic. These findings require confirmation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CLINICAL TRIALS REGISTRATION<\/jats:title>\n                  <jats:p>Trial number NCT00000542.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpy199","type":"journal-article","created":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T20:14:01Z","timestamp":1545682441000},"page":"343-349","source":"Crossref","is-referenced-by-count":2,"title":["The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7044-4166","authenticated-orcid":false,"given":"Joshua I","family":"Barzilay","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Kaiser Permanente of Georgia and Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejian","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas School of Public Health, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry R","family":"Davis","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, University of Texas School of Public Health, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pressel","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, University of Texas School of Public Health, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah E","family":"Previn","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas School of Public Health, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna K","family":"Arnett","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Kentucky College of Public Health, Lexington, Kentucky, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,26]]},"reference":[{"key":"2022111018430513900_CIT0001","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00004872-199715011-00003","article-title":"Epidemiology of hypertension and insulin resistance syndrome","volume":"15","author":"Haffner","year":"1997","journal-title":"J Hypertens Suppl"},{"key":"2022111018430513900_CIT0002","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1097\/00005344-199000005-00004","article-title":"Essential hypertension: an insulin-resistant state","volume":"15","author":"Ferrannini","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022111018430513900_CIT0003","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/DMSO.S51325","article-title":"Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review","volume":"6","author":"Colosia","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022111018430513900_CIT0004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2337\/diacare.27.1.247","article-title":"Antihypertensive therapy and incidence of type 2 diabetes: a systematic review","volume":"27","author":"Padwal","year":"2004","journal-title":"Diabetes Care"},{"key":"2022111018430513900_CIT0005","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"key":"2022111018430513900_CIT0006","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/archinte.166.20.2191","article-title":"Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"166","author":"Barzilay","year":"2006","journal-title":"Arch Intern Med"},{"key":"2022111018430513900_CIT0007","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1210\/jc.2008-1345","article-title":"Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008","volume":"93","author":"Florez","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2022111018430513900_CIT0008","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"2022111018430513900_CIT0009","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"2022111018430513900_CIT0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.tpj.6500113","article-title":"Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study","volume":"2","author":"Arnett","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"2022111018430513900_CIT0011","doi-asserted-by":"crossref","first-page":"e0140496","DOI":"10.1371\/journal.pone.0140496","article-title":"Drug-gene interactions of antihypertensive medications and risk of incident cardiovascular disease: a pharmacogenomics study from the CHARGE consortium","volume":"10","author":"Bis","year":"2015","journal-title":"PLoS One"},{"key":"2022111018430513900_CIT0012","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1056\/NEJMoa0804742","article-title":"Genotype score in addition to common risk factors for prediction of type 2 diabetes","volume":"359","author":"Meigs","year":"2008","journal-title":"N Engl J Med"},{"key":"2022111018430513900_CIT0013","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1007\/s00125-012-2637-7","article-title":"A genotype risk score predicts type 2 diabetes from young adulthood: the CARDIA study","volume":"55","author":"Vassy","year":"2012","journal-title":"Diabetologia"},{"key":"2022111018430513900_CIT0014","doi-asserted-by":"crossref","first-page":"b4838","DOI":"10.1136\/bmj.b4838","article-title":"Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study","volume":"340","author":"Talmud","year":"2010","journal-title":"BMJ"},{"key":"2022111018430513900_CIT0015","doi-asserted-by":"crossref","first-page":"e1002546","DOI":"10.1371\/journal.pmed.1002546","article-title":"Cardiovascular disease: the rise of the genetic risk score","volume":"15","author":"Knowles","year":"2018","journal-title":"PLoS Med"},{"key":"2022111018430513900_CIT0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","article-title":"Thiazide diuretics, potassium, and the development of diabetes: a quantitative review","volume":"48","author":"Zillich","year":"2006","journal-title":"Hypertension"},{"key":"2022111018430513900_CIT0017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.7326\/M13-1522","article-title":"Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician\u2019s guide","volume":"160","author":"Leening","year":"2014","journal-title":"Ann Intern Med"},{"key":"2022111018430513900_CIT0018","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db10-1119","article-title":"Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program","volume":"60","author":"Hivert","year":"2011","journal-title":"Diabetes"},{"key":"2022111018430513900_CIT0019","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1074248414530508","article-title":"Calcium channel blockers in cardiovascular pharmacotherapy","volume":"19","author":"Godfraind","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2022111018430513900_CIT0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/bj2490401","article-title":"Different insulin-secretory responses to calcium-channel blockers in islets of lean and obese (ob\/ob) mice","volume":"249","author":"Black","year":"1988","journal-title":"Biochem J"},{"key":"2022111018430513900_CIT0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/DMSO.S49767","article-title":"Effect of calcium channel blockers on incidence of diabetes: a meta-analysis","volume":"6","author":"Noto","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022111018430513900_CIT0022","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCOUTCOMES.111.962522","article-title":"Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study","volume":"5","author":"Barzilay","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2022111018430513900_CIT0023","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(98)12030-5","article-title":"Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria","volume":"354","author":"Barzilay","year":"1999","journal-title":"Lancet"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/32\/4\/343\/46949995\/ajh_32_4_343.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/32\/4\/343\/46949995\/ajh_32_4_343.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T18:43:45Z","timestamp":1668105825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/32\/4\/343\/5261976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,26]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12,26]]},"published-print":{"date-parts":[[2019,3,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpy199","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"type":"print","value":"0895-7061"},{"type":"electronic","value":"1941-7225"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,12,26]]}}}